More Galleries
6 designers shaking up fashion These designers are changing the way we dress, accessorize and shop, from custom made-to-fit dresses to smart jewelry that's actually stylish. More
8 must-have travel apps Whether you've got wanderlust or an airline grievance, here are some apps to pack onto your phone. More
Secrets to success from Smalltown USA Utah State professor Michael Glauser cycled 4,000 miles this summer, visiting 100 entrepreneurs across the country. Here's a snapshot of how they grew their businesses. More

Special Offer
11 of 36
A novel treatment for a damaged heart
A novel treatment for a damaged heart
Gokul Kumar and Darius Kaullius
Team name: BioRegenix

School: University of Illinois at Chicago, College of Business Administration

Team members: Gokul Kumar, Darius Kaullius, Thomas Triantafillou

Concept: Acute Coronary Syndrome, an umbrella term for chronic heart-muscle injuries that put victims at risk for heart attacks, plagues 2.6 million Americans each year. BioRegenix, a startup formed by a group of medical students and MBAs at the University of Chicago at Illinois, offers a novel therapy to repair damaged heart tissue.

BioRegenix's CardioGen product combines a physical "scaffold" for stem-cell growth with a hormone that induces muscle expansion. BioRegenix's founders predict that this combination will stimulate stem cells already in the body to regenerate damaged tissue, thus repairing heart function.

BioRegenix faces steep odds. The team itself acknowledges that only 8% of pre-clinical pharmaceuticals succeed. But if it works, CardioGen could tap a massive market: Heart disease is the leading cause of death in the U.S.

Timeline: BioRegenix plans to continue its research work through the next two years, then begin the FDA approval process with Phase I clinical testing in 2010. - Mina Kimes

NEXT: A breakthrough board for snow bunnies

Last updated May 02 2008: 11:51 AM ET
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.